Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer |
Min, Kyung-Nan
(College of Pharmacy, Ewha Womans University)
Joung, Ki-Eun (College of Pharmacy, Ewha Womans University) Kim, Dae-Kee (College of Pharmacy, Ewha Womans University) Sheen, Yhun-Yhong (College of Pharmacy, Ewha Womans University) |
1 | Roth, S. Y., Denu, J. M. and Allis, C. D. (2001) Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120. DOI |
2 | Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599-606. DOI ScienceOn |
3 | Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I. and Coombes, R. C. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7, 971-976. |
4 | Vigushin, D. M. and Coombes, R. C. (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13, 1-13. DOI |
5 | Villar-Garea, A. and Esteller, M. (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 112, 171-178. DOI |
6 | Johnstone, R. W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug. Discov. 1, 287-299. DOI ScienceOn |
7 | Johnstone, R. W. and Licht, J.D. (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18. DOI ScienceOn |
8 | Kouzarides, T. (2000) Acetylation: a regulatory modifi cation to rival phosphorylation? EMBO J. 19, 1176-1179. DOI ScienceOn |
9 | Marks, P.A., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. and Kelly, W.K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202. DOI ScienceOn |
10 | Kramer, O. H., Göttlicher, M. and Heinzel, T. (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12, 294-300. DOI |
11 | Qui, L., Kelso, M. J., Hansen, C., West, M. L., Fairlie, D. P. and Parson, P. G. (1999) Anti-tumouractivity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80, 1252-1258. DOI ScienceOn |
12 | Reynisdóttir, I., Polyak, K., Iavarone, A. and Massague, J. (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9, 1831-1845. DOI ScienceOn |
13 | Richon, V. M., Sandhoff, T. W., Rifkind, R. A. and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014-10019. DOI ScienceOn |
14 | Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B. and Grant, S. (2001) Evidence of a functional role forthe cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. 19, 181-191. |
15 | Finzer, P., Kuntzen, C., Soto, U., zur Hausen, H. and Rosl, F. (2001) Inhibitors of histone deacetylasearrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20, 4768-4776. DOI |
16 | Fournel, M., Trachy-Bourget, M. C., Yan, P. T., Kalita, A., Bonfi ls, C., Beaulieu, C., Frechette, S., Leit, S., Abou-Khalil, E., Woo, S. H., Delorme, D., MacLeod, A. R., Besterman, J. M. and Li, Z. (2002) Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 62, 4325-4330. |
17 | Gray, S. G. and Ekström, T. J. (2001) The human histone deacetylase family. Exp. Cell Res. 262, 75-83. DOI ScienceOn |
18 | Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M. and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98, 87-92. DOI |
19 | Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G. and Davidsen,S. K. (2003) Gene expression profi ling of multiple histone deacetylase (HDAC) inhibitors: defi ning a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163. DOI |
20 | Gottlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G. and Heinzel, T. (2001) Valproicacid defi nes a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978. DOI ScienceOn |
21 | Grunstein, M. (1997) Histone acetylation in chromatin structure and transcription. Nature 389, 349-352. DOI ScienceOn |
22 | Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M. and Marks, P. A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101, 1241-1246. DOI |
23 | Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T. R., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon-Cardo, C., Scher, H. I., Breslow, R., Richon, V. M., Rifkind, R. A. and Marks, P. A. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962-970. |
24 | Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. and La Thangue, N. B. (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3, 667-674. DOI ScienceOn |
25 | de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. and van Kuilenburg, A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749. DOI ScienceOn |
26 | Cress, W. D. and Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184, 1-16. DOI ScienceOn |
27 | David, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A. and Dejean, A. (1998) Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16, 2549-2556. DOI ScienceOn |
28 | Davis, T., Kennedy, C., Chiew, Y. E., Clarke, C. L. and deFazio, A. (2000) Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 6, 4334-4342. |
29 | Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K. and Benz, C. C. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528. DOI |
30 | Finnin, M. S., Donigian, J. R. and Pavletich, N. P. (2001) Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 8, 621-625. DOI ScienceOn |
31 | Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E. and Fornace, A, J. Jr. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36, 343-350. DOI |
32 | Archer. S. Y., Meng. S., Shei. A. and Hodin. R. A. (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95, 6791-6796. DOI |
33 | Banwell, C. M., Singh, R., Stewart, P. M., Uskokovic, M. R. and Campbell, M. J. (2003) Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 164, 83-98. DOI |
34 | Blobel, G. A. (2000) CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95, 745-755. |
35 | Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon- Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A. and Richon, V. M. (2000a) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170. |
36 | Butler, L. M., Higgins, B., Fox, W. D., Agus, D. B., Cordon-Cardo, C. and Scher, H. J. (2000b) Hybrid polar inhibitors of histone deacetylase suppress the growth of the CWR22 human prostate cancer xenograft. Proc. Am. Assoc. Cancer Res. 41, 289. |